BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following upcoming investor conferences:
- 41st Annual Deutsche Bank Health Care Conference in Boston, MA on Wednesday, May 4, 2016, at 10:00 am Eastern Time
- 2016 Bank of America Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016 at 11:20 am Pacific Time
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro’s website at www.aduro.com.
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro’s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro’s STING pathway activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
CONTACT: Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 firstname.lastname@example.org Mike Beyer Sam Brown, Inc. 312 961 2502